RAD-140 and Tamoxifen Interaction

Avoid
Mechanism-based 53% confidence

RAD-140 and Tamoxifen have a potentially harmful interaction with 53% confidence. Both RAD-140 and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads, so monitoring these systems is recommended.

Compound Profiles

RAD-140

Selective Androgen Receptor Modulator | Investigational SARM

RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist activity in the prostate and other androgen-sensitive tissues. This tissue selectivity is achieved through differential cofactor recruitment: upon binding to the AR, RAD-140 induces a conformational change that favors interaction with coactivators predominantly expressed in skeletal muscle and bone, rather than those prevalent in prostate or sebaceous glands.

Half-life: ~60 hours Typical dose: 10-20 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskcrosses bbb
View full profile

Tamoxifen

Selective Estrogen Receptor Modulator | PCT & Breast Cancer Treatment

Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling.

Half-life: ~5-7 days Typical dose: 20-40mg oral daily pct
cyp3a4estrogen receptor anticoagulantcarcinogenic riskhepatotoxicpct agent
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (RAD-140, Tamoxifen). Monitor accordingly.
2x 2 hepatotoxic compounds (RAD-140, Tamoxifen). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.

Frequently Asked Questions

Can I take RAD-140 with Tamoxifen?

Combining RAD-140 with Tamoxifen is not recommended. Both RAD-140 and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is RAD-140 and Tamoxifen safe together?

This combination carries significant risk. Both RAD-140 and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between RAD-140 and Tamoxifen?

Both RAD-140 and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 53% confidence and is inferred from pharmacological mechanism analysis.

How should I time RAD-140 and Tamoxifen?

RAD-140 has a half-life of ~60 hours and Tamoxifen has a half-life of ~5-7 days. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: RAD-140 vs Tamoxifen

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.